{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Svetlova J"],"funding":["Russian Science Foundation"],"pagination":["13220"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9655829"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(21)"],"pubmed_abstract":["Mutations in surface proteins enable emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to escape a substantial fraction of neutralizing antibodies and may thus weaken vaccine-driven immunity. To compare available vaccines and justify revaccination, rapid evaluation of antibody (Ab) responses to currently circulating SARS-CoV-2 variants of interest (VOI) and concern (VOC) is needed. Here, we developed a multiplex protein microarray-based system for rapid profiling of anti-SARS-CoV-2 Ab levels in human sera. The microarray system was validated using sera samples from SARS-CoV-2-free donors and those diagnosed with COVID-19 based on PCR and enzyme immunoassays. Microarray-based profiling of vaccinated donors revealed a substantial difference in anti-VOC Ab leve"],"journal":["International journal of molecular sciences"],"pubmed_title":["Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern."],"pmcid":["PMC9655829"],"funding_grant_id":["22-25-00420"],"pubmed_authors":["Kharlampieva D","Gustin D","Shirokov D","Svetlova J","Varizhuk A","Lazarev V","Shokina V","Vedekhina T","Manuvera V","Matyushkina D","Aldarov K","Bespyatykh J","Prusakov K"],"additional_accession":[]},"is_claimable":false,"name":"Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern.","description":"Mutations in surface proteins enable emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to escape a substantial fraction of neutralizing antibodies and may thus weaken vaccine-driven immunity. To compare available vaccines and justify revaccination, rapid evaluation of antibody (Ab) responses to currently circulating SARS-CoV-2 variants of interest (VOI) and concern (VOC) is needed. Here, we developed a multiplex protein microarray-based system for rapid profiling of anti-SARS-CoV-2 Ab levels in human sera. The microarray system was validated using sera samples from SARS-CoV-2-free donors and those diagnosed with COVID-19 based on PCR and enzyme immunoassays. Microarray-based profiling of vaccinated donors revealed a substantial difference in anti-VOC Ab leve","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-25T23:22:47.639Z","creation":"2025-04-06T09:23:08.035Z"},"accession":"S-EPMC9655829","cross_references":{"pubmed":["36362010"],"doi":["10.3390/ijms232113220"]}}